flurbiprofen has been researched along with Disease Exacerbation in 9 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most common adverse events were diarrhoea (in seven, nine, and five patients in the 800 mg, 400 mg, and placebo groups, respectively), nausea (in seven, seven, and four patients), and dizziness (in five, nine, and four patients)." | 2.73 | Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. ( Black, SE; Hendrix, SB; Laughlin, MA; Swabb, EA; Wilcock, GK; Zavitz, KH, 2008) |
| "Our results establish that the neurotoxicity related to the Abeta peptide can be captured in vivo by functional imaging and suggest hippocampal subregions most vulnerable to its toxic effects." | 1.34 | Imaging the Abeta-related neurotoxicity of Alzheimer disease. ( Brickman, A; Brown, TR; Lee, T; Mayeux, R; Moreno, H; Small, SA; Wu, WE, 2007) |
| "Periodontitis was induced in 30 dogs (groups 2-6) by ligating the bilateral mandibular third and fourth premolar teeth with silk ligatures and by feeding a soft diet." | 1.30 | Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs. ( Abe, T; Fujikura, T; Kanoh, H; Matsue, I; Matsue, M; Motoie, H; Nishikawa, H; Nishimori, E; O'uchi, N; Shikama, H; Shimaoka, T; Yoshino, T, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| de Bruin, N | 1 |
| Schneider, AK | 1 |
| Reus, P | 1 |
| Talmon, S | 1 |
| Ciesek, S | 1 |
| Bojkova, D | 1 |
| Cinatl, J | 1 |
| Lodhi, I | 1 |
| Charlesworth, B | 1 |
| Sinclair, S | 1 |
| Pennick, G | 1 |
| Laughey, WF | 1 |
| Gribbon, P | 1 |
| Kannt, A | 1 |
| Schiffmann, S | 1 |
| Wan, HI | 1 |
| Jacobsen, JS | 1 |
| Rutkowski, JL | 1 |
| Feuerstein, GZ | 1 |
| Shankle, WR | 1 |
| Hara, J | 1 |
| Mangrola, T | 1 |
| Hendrix, S | 1 |
| Alva, G | 1 |
| Lee, MD | 1 |
| Nessim, M | 1 |
| Kyprianou, I | 1 |
| Kumar, V | 1 |
| Murray, PI | 1 |
| Moreno, H | 1 |
| Wu, WE | 1 |
| Lee, T | 1 |
| Brickman, A | 1 |
| Mayeux, R | 1 |
| Brown, TR | 1 |
| Small, SA | 1 |
| Wilcock, GK | 1 |
| Black, SE | 1 |
| Hendrix, SB | 1 |
| Zavitz, KH | 1 |
| Swabb, EA | 1 |
| Laughlin, MA | 1 |
| O'uchi, N | 1 |
| Nishikawa, H | 1 |
| Yoshino, T | 1 |
| Kanoh, H | 1 |
| Motoie, H | 1 |
| Nishimori, E | 1 |
| Shimaoka, T | 1 |
| Abe, T | 1 |
| Shikama, H | 1 |
| Fujikura, T | 1 |
| Matsue, M | 1 |
| Matsue, I | 1 |
| Wechter, WJ | 1 |
| Leipold, DD | 1 |
| Murray, ED | 1 |
| Quiggle, D | 1 |
| McCracken, JD | 1 |
| Barrios, RS | 1 |
| Greenberg, NM | 1 |
| Paquette, DW | 1 |
| Williams, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Non-Steroidal Anti-Inflammatory Drugs as a Tool of Positive Change in Peri-Implants Mucositis Microbiome[NCT03090009] | Early Phase 1 | 100 participants (Anticipated) | Interventional | 2017-04-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flurbiprofen and Disease Exacerbation
| Article | Year |
|---|---|
Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Cyclooxygenase 2; Cyclooxygenas | 2000 |
1 trial available for flurbiprofen and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secreta | 2008 |
7 other studies available for flurbiprofen and Disease Exacerbation
| Article | Year |
|---|---|
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.
Topics: Acetaminophen; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ca | 2022 |
Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
Topics: Alzheimer Disease; Animals; Biomarkers; Clinical Trials as Topic; Disease Progression; Drug Discover | 2009 |
Hierarchical Bayesian cognitive processing models to analyze clinical trial data.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Amyloid Precursor P | 2013 |
Anterior scleritis, scleral thinning, and intraocular pressure measurement.
Topics: Anti-Inflammatory Agents; Disease Progression; Drug Therapy, Combination; Female; Flurbiprofen; Huma | 2005 |
Imaging the Abeta-related neurotoxicity of Alzheimer disease.
Topics: Aged, 80 and over; Algorithms; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precur | 2007 |
Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs.
Topics: Alveolar Bone Loss; Alveolar Process; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-S | 1998 |
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
Topics: Adenocarcinoma; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Disease Progression; Flu | 2000 |